Molecular inhibition of prostaglandin E2 with GW627368X: Therapeutic potential and preclinical safety assessment in mouse sarcoma model

References

• Xin X, Majumder M, Girish GV, Mohindra V, Maruyama T, Lala PK. Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model. Laboratory Investigation 2012; 92:1115-28; PMID:22641101; http://dx.doi.org/10.1038/labinvest.2012.90
   PubMed Web of Science ®Google Scholar
• Fulton AM, Ma X, Kundu N. Targeting prostaglandin E EP receptors to inhibit metastasis. Cancer Res 2006; 66:9794-7; PMID:17047037; http://dx.doi.org/10.1158/0008-5472.CAN-06-2067
   PubMed Web of Science ®Google Scholar
• Ricciotti E, FitzGerald GA. Prostaglandin and inflammation. Arterioscler Thromb Vasc Biol 2011; 31:986-1000; PMID:21508345; http://dx.doi.org/10.1161/ATVBAHA.110.207449
   PubMed Web of Science ®Google Scholar
• Fries S, Grosser T. The cardiovascular pharmacology of COX-2 inhibition. Hematology 2005; 2005:445-51; PMID:16304418; http://dx.doi.org/10.1182/asheducation-2005.1.445
   PubMedGoogle Scholar
• Ma X, Holt D, Kundu N, Reader J, Goloubeva O, Take Y, Fulton AM. A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE2-mediated immunosuppression and inhibits breast cancer metastasis. OncoImmunology 2013; 2:e22647; PMID:23482441; http://dx.doi.org/10.4161/onci.22647
   PubMed Web of Science ®Google Scholar
• Zhao L, Wu Y, Xu Z, Wang H, Zhao Z, Li Y, Yang P, Wei X. Involvement of COX-2/PGE2 signalling in hypoxia-induced angiogenic response in endothelial cells. J Cell Mol Med 2012; 16:1840-55; PMID:22050691; http://dx.doi.org/10.1111/j.1582-4934.2011.01479.x
   PubMed Web of Science ®Google Scholar
• Hull MA, Ko SC, Hawcroft G. Prostaglandin EP receptors: Targets for treatment and prevention of colorectal cancer? Mol Cancer Ther 2004; 3:1031-9; PMID:15299086; http://dx.doi.org/10.4161/cbt.3.10.1227
   PubMed Web of Science ®Google Scholar
• Leduc M, Breton B, Gale´s C, Gouill CL, Bouvier M, Chemtob S, Heveker N. Functional selectivity of natural and synthetic prostaglandin EP4 receptor ligands. J Pharmacol Exp Thera 2009; 331:297-307; PMID:19584306; http://dx.doi.org/10.1124/jpet.109.156398
   PubMed Web of Science ®Google Scholar
• Yokoyama U, Iwastubo K, Umemura M, Fujita T, Ishikawa Y. The prostanoid EP4 receptor and its signaling pathway. Pharmacol Rev 2013; 65:1010-52; PMID:23776144; http://dx.doi.org/10.1124/pr.112.007195
   PubMed Web of Science ®Google Scholar
• Coleman RA, Grix SP, Head SA, Louttit JB, Mallett A, Sheldrick RL. A novel inhibitory prostanoid receptor in piglet saphenous vein. Prostaglandins 1994; 47:151-68; PMID:8016385; http://dx.doi.org/10.1016/0090-6980(94)90084-1
   PubMed Web of Science ®Google Scholar
• Coleman RA, Smith WL, Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 1994; 46:205-29; PMID:7938166
   PubMed Web of Science ®Google Scholar
• Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, Paraskeva C, Kaidi A. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009; 30:377-86; PMID:19136477; http://dx.doi.org/10.1093/carcin/bgp014
   PubMed Web of Science ®Google Scholar
• Mosa AS, Hansen MB, Tilotta CM, Bindslev N. EP4 and EP2 receptor subtypes involved in colonic secretion in rat. Basic Clin Pharmacol Toxicol 2008; 103:214-21; PMID:18684231; http://dx.doi.org/10.1111/j.1742-7843.2008.00257.x
   PubMed Web of Science ®Google Scholar
• Wilson RJ, Giblin GM, Roomans S, Rhodes SA, Cartwright KA, Shield VJ, Brown J, Wise A, Chowdhury J, Pritchard S, et al. GW627368X ((N-{2-[4-(4,9-diethoxy-1-oxo-1,3-dihydro-2Hbenzo[f]isoindol-2-yl)phenyl]acetyl} benzene sulphonamide): a novel, potent and selective prostanoid EP4 receptor antagonist. Br J Pharmacol 2006; 148:326-39; PMID:16604093; http://dx.doi.org/10.1038/sj.bjp.0706726
   PubMed Web of Science ®Google Scholar
• Robertson FM, Simeone AM, Mazumdar A, Shah AH, McMurray JS, Ghosh S, Cristofanilll M. Molecular and pharmacological blockade of the EP4 receptor selectively inhibits both proliferation and invasion of human inflammatory breast cancer cells. J Exp Thera Oncol 2008; 7:299-312; PMID:19227010
   PubMedGoogle Scholar
• Reader J, Holt D, Fulton A. Prostaglandin E2 EP receptors as therapeutic targets in breast cancer. Cancer Metastasis Rev 2011; 30:449-63; PMID:22002714; http://dx.doi.org/10.1007/s10555-011-9303-2
   PubMed Web of Science ®Google Scholar
• Parida S, Mandal M. Inflammation induced by human papilloma virus in cervical cancer and its implication in prevention. Eur J Cancer Prev 2014; 23:432-48; PMID:24787377
   PubMed Web of Science ®Google Scholar
• Fairbrother SE, Smith JE, Borman RA, Helen M. Cox EP4 receptors mediate prostaglandin E2, tumour necrosis factor alpha and interleukin 1beta-induced ion secretion in human and mouse colon mucosa. Eur J Pharmacol 2012; 694:89-97; PMID:22732652; http://dx.doi.org/10.1016/j.ejphar.2012.06.020
   PubMed Web of Science ®Google Scholar
• Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN. Cyclooxygenase-2 and eidermal growth factor peceptor: pharmacologic targets for chemoprevention. J Clin Oncol 2005; 23:254-66; PMID:15637389; http://dx.doi.org/10.1200/JCO.2005.09.112
   PubMed Web of Science ®Google Scholar
• Pidgeon GP, Barr MP, Harmey JH, Foley DA, Bouchier-Hayes DJ. Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells. Br J Cancer 2001; 85:273-8; PMID:11461089; http://dx.doi.org/10.1054/bjoc.2001.1876
   PubMed Web of Science ®Google Scholar
• Nor JE, Christenesen J, Mooney DJ, Polvereni PJ. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol 1999; 154:375-84; PMID:10027396; http://dx.doi.org/10.1016/S0002-9440(10)65284-4
   PubMed Web of Science ®Google Scholar
• Biroccio A, Candiloro A, Mottolese M, Sapora O, Albini A, Zupi G, Bufalo DD. Bcl-2 overexpression and hypoxia synergistically act to modulate vascular endothelial growth factor expression and in vivo angiogenesis in a breast carcinoma line. FASEB 2000; 14:652-60; PMID:10744622
   PubMed Web of Science ®Google Scholar
• De Keijzer S, Meddens MB, Torensma R, Cambi A. The multiple faces of prostaglandin E2 G-Protein coupled receptor signaling during the dendritic cell life cycle. Int J Mol Sci 2013; 14:6542-55; PMID:23528886; http://dx.doi.org/10.3390/ijms14046542
   PubMed Web of Science ®Google Scholar
• Rajput S, Kumar BN, Sarkar S, Das S, Azab B, Santhekadur PK, Das SK, Emdad L, Sarkar D, Fisher PB, et al. Targeted apoptotic effects of thymoquinone and tamoxifen on XIAP mediated Akt regulation in breast cancer. PLoS One 2013; 8:e61342; PMID:23613836; http://dx.doi.org/10.1371/journal.pone.0061342
   PubMed Web of Science ®Google Scholar
• Kumar BN, Rajput S, Dey KK, Parekh A, Das S, Mazumdar A, Mandal M. Celecoxib alleviates tamoxifen-instigated angiogenic effects by ROS-dependent VEGF/VEGFR2 autocrine signaling. BMC Cancer 2013; 13:273; PMID:23731702; http://dx.doi.org/10.1186/1471-2407-13-273
   PubMed Web of Science ®Google Scholar
• Messinger H, Bar A. Oral 4-week and 13-week toxicity studies of polyvinyl acetate vinyl laurate copolymer in rats. Regul Toxicol Pharmacol 2014; 70:1-6; PMID:24932800; http://dx.doi.org/10.1016/j.yrtph.2014.06.008
   PubMed Web of Science ®Google Scholar
• Clarke K, Tchabanenko K, Pawlosky R, Carter E, Knight NS, Murray AJ, Cochlin LE, Todd King M, Wong AW, Roberts A, et al. Oral 28-day and developmental toxicity studies of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate. Regul Toxicol Pharmacol 2012; 63:196-208; PMID:22504461; http://dx.doi.org/10.1016/j.yrtph.2012.04.001
   PubMed Web of Science ®Google Scholar
• Nandi U, Karmakar S, Das AK, Ghosh B, Padman A, Chatterjee N, Pal TK. Pharmacokinetics, pharmacodynamics and toxicity of a combination of metoprolol succinate and telmisartan in Wistar albino rats: Safety profiling. Regul Toxicol Pharmacol 2013; 65:68-78; PMID:23201407; http://dx.doi.org/10.1016/j.yrtph.2012.11.001
   PubMed Web of Science ®Google Scholar
• Li Z, Qiao Y, Li J, An C, Hud K, Tang M. Acute and sub-chronic toxicity studies of the extract of Thunberg Fritillary Bulb. Regul Toxicol Pharmacol 2014; 68:370-7; PMID:24486111; http://dx.doi.org/10.1016/j.yrtph.2014.01.007
   PubMed Web of Science ®Google Scholar